Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 1
Submit an article Journal homepage
153
Views
1
CrossRef citations to date
0
Altmetric
Review

Personalized Dendritic Cell-Based Tumor Immunotherapy

Nona Janikashvili1 Department of Pediatrics, Steele Children‘s Research Center, Arizona85724, USAView further author information
,
Nicolas Larmonier1 Department of Pediatrics, Steele Children‘s Research Center, Arizona85724, USA;2 Department of Immunobiology, BIO5 Institute & Arizona Cancer Center, University of Arizona, Tucson, AZ85724, USAView further author information
&
Emmanuel Katsanis1 Department of Pediatrics, Steele Children‘s Research Center, Arizona85724, USA;2 Department of Immunobiology, BIO5 Institute & Arizona Cancer Center, University of Arizona, Tucson, AZ85724, USA;3 University of Arizona, Department of Pediatrics, 1501 N Campbell Ave, PO Box 245073, Tucson, AZ85724-85073, USA. Tel.: +1 520 626 5260 Fax: +1 520 626 [email protected]View further author information
Pages 57-68 | Published online: 17 Dec 2009

Bibliography

  • Banchereau J , PaluckaAK: Dendritic cells as therapeutic vaccines against cancer.Nat. Rev. Immunol.5 , 296–306 (2005).
  • Banchereau J , SteinmanRM: Dendritic cells and the control of immunity.Nature392 , 245–252 (1998).
  • Palucka AK , UenoH, FayJ, BanchereauJ: Dendritic cells: a critical player in cancer therapy?J. Immunother.31 , 793–805 (2008).
  • Gilboa E , NairSK, LyerlyHK: Immunotherapy of cancer with dendritic cell-based vaccines.Cancer Immunol. Immunother.46 , 82–87 (1998).
  • Nestle FO , FarkasA, ConradC: Dendritic-cell-based therapeutic vaccination against cancer.Curr. Opin. Immunol.17 , 163–169 (2005).
  • Palucka AK , LaupezeB, AspordC et al.: Immunotherapy via dendritic cells.Adv. Exp. Med. Biol.560 , 105–114 (2005).
  • Mayordomo JI , ZorinaT, StorkusWJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.Nat. Med.1 , 1297–1302 (1995).
  • Nagaraj S , ZiskeC, StrehlJ, MessmerD, SauerbruchT, Schmidt-WolfIG: Dendritic cells pulsed with α-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo.Int. Immunol.18 , 1279–1283 (2006).
  • Shimizu J , SudaT, YoshiokaT, KosugiA, FujiwaraH, HamaokaT: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.J. Immunol.142 , 1053–1059 (1989).
  • Paczesny S , UenoH, FayJ, BanchereauJ, PaluckaAK: Dendritic cells as vectors for immunotherapy of cancer.Semin. Cancer Biol.13 , 439–447 (2003).
  • Figdor CG , de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med.10 , 475–480 (2004).
  • Steinman RM , BanchereauJ: Taking dendritic cells into medicine.Nature449 , 419–426 (2007).
  • Disis ML , CheeverMA: HER-2/neu oncogenic protein: issues in vaccine development.Crit. Rev. Immunol.18 , 37–45 (1998).
  • Disis ML , GooleyTA, RinnK et al.: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.J. Clin. Oncol.20 , 2624–2632 (2002).
  • Cibotti R , KanellopoulosJM, CabaniolsJP et al.: Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants.Proc. Natl Acad. Sci. USA89 , 416–420 (1992).
  • Keogh E , FikesJ, SouthwoodS, CelisE, ChesnutR, SetteA: Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.J. Immunol.167 , 787–796 (2001).
  • Elliott T , CerundoloV, ElvinJ, TownsendA: Peptide-induced conformational change of the class I heavy chain.Nature351 , 402–406 (1991).
  • Sette A , VitielloA, RehermanB et al.: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.J. Immunol.153 , 5586–5592 (1994).
  • Ward S , CaseyD, LabartheMC et al.: Immunotherapeutic potential of whole tumour cells.Cancer Immunol. Immunother.51 , 351–357 (2002).
  • Finn OJ : Cancer vaccines: between the idea and the reality.Nat. Rev. Immunol.3 , 630–641 (2003).
  • Rosenberg SA , YangJC, RestifoNP: Cancer immunotherapy: moving beyond current vaccines.Nat. Med.10 , 909–915 (2004).
  • Rabinovich GA , GabrilovichD, SotomayorEM: Immunosuppressive strategies that are mediated by tumor cells.Annu. Rev. Immunol.25 , 267–296 (2007).
  • Drake CG , JaffeeE, PardollDM: Mechanisms of immune evasion by tumors.Adv. Immunol.90 , 51–81 (2006).
  • Gabrilovich D : Mechanisms and functional significance of tumour-induced dendritic-cell defects.Nat. Rev. Immunol.4 , 941–952 (2004).
  • Feng H , ZengY, GranerMW, LikhachevaA, KatsanisE: Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate anti-tumor immunity.Blood101 , 245–252 (2003).
  • Feng H , ZengY, WhitesellL, KatsanisE: Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity.Blood97 , 3505–3512 (2001).
  • Larmonier N , FraszczakJ, LakomyD, BonnotteB, KatsanisE: Killer dendritic cells and their potential for cancer immunotherapy.Cancer Immunol. Immunother.59(1) , 1–11 (2009).
  • Aarntzen EH , FigdorCG, AdemaGJ, PuntCJ, de Vries IJ: Dendritic cell vaccination and immune monitoring. Cancer Immunol. Immunother.57 , 1559–1568 (2008).
  • Tuyaerts S , AertsJL, CorthalsJ et al.: Current approaches in dendritic cell generation and future implications for cancer immunotherapy.Cancer Immunol. Immunother.56 , 1513–1537 (2007).
  • Inaba K , InabaM, RomaniN et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.J. Exp. Med.176 , 1693–1702 (1992).
  • Schreurs MW , EggertAA, de Boer AJ, Figdor CG, Adema GJ: Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur. J. Immunol.29 , 2835–2841 (1999).
  • Romani N , GrunerS, BrangD et al.: Proliferating dendritic cell progenitors in human blood.J. Exp. Med.180 , 83–93 (1994).
  • Caux C , VanbervlietB, MassacrierC et al.: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF-α.J. Exp. Med.184 , 695–706 (1996).
  • Fay JW , PaluckaAK, PaczesnyS et al.: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells.Cancer Immunol. Immunother.55 , 1209–1218 (2006).
  • Paczesny S , BanchereauJ, WittkowskiKM, SaracinoG, FayJ, PaluckaAK: Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.J. Exp. Med.199 , 1503–1511 (2004).
  • Ashley DM , FaiolaB, NairS, HaleLP, BignerDD, GilboaE: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce anti-tumor immunity against central nervous system tumors.J. Exp. Med.186 , 1177–1182 (1997).
  • Fields RC , ShimizuK, MuleJJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent anti-tumor immune responses in vitro and in vivo.Proc. Natl Acad. Sci. USA95 , 9482–9487 (1998).
  • Geiger C , RegnS, WeinzierlA, NoessnerE, SchendelDJ: A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.J. Transl. Med.3 , 29 (2005).
  • Phan V , ErringtonF, CheongSC et al.: A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines.Nat. Med.9 , 1215–1219 (2003).
  • Sauter B , AlbertML, FranciscoL, LarssonM, SomersanS, BhardwajN: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.J. Exp. Med.191 , 423–434 (2000).
  • Wolfers J , LozierA, RaposoG et al.: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.Nat. Med.7 , 297–303 (2001).
  • Ueda G , TamuraY, HiraiI et al.: Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity.Cancer Sci.95 , 248–253 (2004).
  • Wang XH , QinY, HuMH, XieY: Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.Cancer Immunol. Immunother.54 , 971–980 (2005).
  • Andre F , SchartzNE, MovassaghM et al.: Malignant effusions and immunogenic tumour-derived exosomes.Lancet360 , 295–305 (2002).
  • Waldhauer I , GoehlsdorfD, GiesekeF et al.: Tumor-associated MICA is shed by ADAM proteases.Cancer Res.68 , 6368–6376 (2008).
  • Nencioni A , GrunebachF, SchmidtSM et al.: The use of dendritic cells in cancer immunotherapy.Crit. Rev. Oncol. Hematol.65 , 191–199 (2008).
  • Grunebach F , ErndtS, HantschelM, HeineA, BrossartP: Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells.Cancer Immunol. Immunother.57 , 1483–1491 (2008).
  • Yasuda T , KamigakiT, KawasakiK et al.: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.Cancer Immunol. Immunother.56(7) , 1025–1036 (2006).
  • Kao JY , ZhangM, ChenCM, ChenJJ: Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.Immunol. Lett.101 , 154–159 (2005).
  • Galea-Lauri J , DarlingD, MuftiG, HarrisonP, FarzanehF: Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.Cancer Immunol. Immunother.51 , 299–310 (2002).
  • Shimizu K , KuriyamaH, KjaergaardJ, LeeW, TanakaH, ShuS: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.J. Immunother.27 , 265–272 (2004).
  • Ribas A : Genetically modified dendritic cells for cancer immunotherapy.Curr. Gene Ther.5 , 619–628 (2005).
  • Breckpot K , HeirmanC, NeynsB, ThielemansK: Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.J. Gene Med.6 , 1175–1188 (2004).
  • Todryk SM , BirchallLJ, ErlichR, HalanekN, Orleans-LindsayJK, DalgleishAG: Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.Immunology102 , 190–198 (2001).
  • den Brok MH , NierkensS, FigdorCG, RuersTJ, AdemaGJ: Dendritic cells: tools and targets for anti-tumor vaccination.Expert Rev. Vaccines4 , 699–710 (2005).
  • Adema GJ : Dendritic cells from bench to bedside and back.Immunol. Lett.122 , 128–130 (2009).
  • den Brok MH , SutmullerRP, NierkensS et al.: Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.Cancer Res.66 , 7285–7292 (2006).
  • Hodge JW , RadAN, GrosenbachDW et al.: Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.J. Natl Cancer Inst.92 , 1228–1239 (2000).
  • MartIn-Fontecha A , SebastianiS, HopkenUE et al.: Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming.J. Exp. Med.198 , 615–621 (2003).
  • Nestle FO , AlijagicS, GillietM et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.Nat. Med.4 , 328–332 (1998).
  • Ehtesham M , KabosP, GutierrezMA, SamotoK, BlackKL, YuJS: Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.J. Immunother.26 , 107–116 (2003).
  • Chen M , HuangL, ShabierZ, WangJ: Regulation of the lifespan in dendritic cell subsets.Mol. Immunol.44 , 2558–2565 (2007).
  • Kim TW , LeeJH, HeL et al.: Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency.Cancer Res.65 , 309–316 (2005).
  • de Gruijl TD , van den Eertwegh AJ, Pinedo HM, Scheper RJ: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother.57 , 1569–1577 (2008).
  • O‘Rourke MG , JohnsonM, LanaganC et al.: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.Cancer Immunol. Immunother.52 , 387–395 (2003).
  • Larmonier N , MerinoD, NicolasA et al.: Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading.Apoptosis11 , 1513–1524 (2006).
  • Melero I , VileRG, ColomboMP: Feeding dendritic cells with tumor antigens: self-service buffet or a la carte?Gene Ther.7 , 1167–1170 (2000).
  • Albert ML , SauterB, BhardwajN: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.Nature392 , 86–89 (1998).
  • Schnurr M , ScholzC, RothenfusserS et al.: Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γδ T cells.Cancer Res.62 , 2347–2352 (2002).
  • Jarnjak-Jankovic S , PettersenRD, Saeboe-LarssenS, WesenbergF, OlafsenMR, GaudernackG: Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma.Cancer Gene Ther.12 , 699–707 (2005).
  • Gallucci S , LolkemaM, MatzingerP: Natural adjuvants: endogenous activators of dendritic cells.Nat. Med.5 , 1249–1255 (1999).
  • Basu S , BinderRJ, SutoR, AndersonKM, SrivastavaPK: Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway.Int. Immunol.12 , 1539–1546 (2000).
  • Nicolas A , CathelinD, LarmonierN et al.: Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism.J. Immunol.179 , 812–818 (2007).
  • Kalos M : Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects.Vaccine21 , 781–786 (2003).
  • Zeng Y , GranerMW, KatsanisE: Chaperone-rich cell lysates, immune activation and tumor vaccination.Cancer Immunol. Immunother.55 , 329–338 (2006).
  • Gilboa E : The risk of autoimmunity associated with tumor immunotherapy.Nat. Immunol.2 , 789–792 (2001).
  • Bos R , van Duikeren S, Morreau H et al.: Balancing between anti-tumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res.68 , 8446–8455 (2008).
  • Thomas-Kaskel AK , WallerCF, Schultze-SeemannW, VeelkenH: Immunotherapy with dendritic cells for prostate cancer.Int. J. Cancer121 , 467–473 (2007).
  • Nencioni A , MullerMR, GrunebachF et al.: Dendritic cells transfected with tumor RNA for the induction of anti-tumor CTL in colorectal cancer.Cancer Gene Ther.10 , 209–214 (2003).
  • Muller MR , GrunebachF, NencioniA, BrossartP: Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes.J. Immunol.170 , 5892–5896 (2003).
  • Holtl L , Zelle-RieserC, GanderH et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.Clin. Cancer Res.8 , 3369–3376 (2002).
  • Ruffini PA , NeelapuSS, KwakLW, BiragynA: Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.Haematologica87 , 989–1001 (2002).
  • Miller RA , MaloneyDG, WarnkeR, LevyR: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.N. Engl. J. Med.306 , 517–522 (1982).
  • Meeker T , LowderJ, ClearyML et al.: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.N. Engl. J. Med.312 , 1658–1665 (1985).
  • Houot R , LevyR: Vaccines for lymphomas: idiotype vaccines and beyond.Blood Rev23 , 137–142 (2009).
  • Timmerman JM , CzerwinskiDK, DavisTA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.Blood99 , 1517–1526 (2002).
  • Blachere NE , SrivastavaPK: Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors.Semin. Cancer Biol.6 , 349–355 (1995).
  • Suto R , SrivastavaPK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides.Science269 , 1585–1588 (1995).
  • Asea A , KraeftSK, Kurt-JonesEA et al.: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine.Nat. Med.6 , 435–442 (2000).
  • Graner M , RaymondA, RomneyD, HeL, WhitesellL, KatsanisE: Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma.Clin. Cancer Res.6 , 909–915 (2000).
  • Udono H , SrivastavaPK: Heat shock protein 70-associated peptides elicit specific cancer immunity.J. Exp. Med.178 , 1391–1396 (1993).
  • Udono H , SrivastavaPK: Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70.J. Immunol.152 , 5398–5403 (1994).
  • Nair S , WearschPA, MitchellDA, WassenbergJJ, GilboaE, NicchittaCV: Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.J. Immunol.162 , 6426–6432 (1999).
  • Basu S , SrivastavaPK: Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity.J. Exp. Med.189 , 797–802 (1999).
  • Arnold D : Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96.J. Exp. Med.182 , 885–889 (1995).
  • Li Z , QiaoY, LiuB et al.: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.Clin. Cancer Res.11 , 4460–4468 (2005).
  • Rivoltini L , CastelliC, CarrabbaM et al.: Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.J. Immunol.171 , 3467–3474 (2003).
  • Belli F , TestoriA, RivoltiniL et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.J. Clin. Oncol.20 , 4169–4180 (2002) (Erratum appears in J. Clin. Oncol.20(23) , 4610 [2002]).
  • Udono H , SrivastavaPK: Heat shock protein 70-associated peptides elicit specific cancer immunity.J. Exp. Med.178 , 1391–1396 (1993).
  • Nair S , WearschPA, MitchellDA, WassenbergJJ, GilboaE, NicchittaCV: Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.J. Immunol.162 , 6426–6432 (1999).
  • Arnold D , FaathS, RammenseeH, SchildH: Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96.J. Exp. Med.182 , 885–889 (1995).
  • Srivastava PK , UdonoH: Heat shock protein-peptide complexes in cancer immunotherapy.Curr. Opin. Immunol.6 , 728–732 (1994).
  • Srivastava PK , MenoretA, BasuS, BinderRJ, McQuadeKL: Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world.Immunity8 , 657–665 (1998).
  • Ishii T , UdonoH, YamanoT et al.: Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96.J. Immunol.162 , 1303–1309 (1999).
  • Zeng Y , ChenX, LarmonierN et al.: Natural killer cells play a key role in the anti-tumor immunity generated by chaperone-rich cell lysate vaccination.Int. J. Cancer119 , 2624–2631 (2006).
  • Graner M , RaymondA, AkporiayeE, KatsanisE: Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent anti-tumor vaccines.Cancer Immunol. Immunother.49 , 476–484 (2000).
  • Graner MW , LikhachevaA, DavisJ et al.: Cargo from tumor-expressed albumin inhibits T-cell activation and responses.Cancer Res.64 , 8085–8092 (2004).
  • Graner MW , ZengY, FengH, KatsanisE: Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.Cancer Immunol. Immunother.52 , 226–234 (2003).
  • Zeng Y , FengH, GranerMW, KatsanisE: Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent anti-tumor immunity.Blood101 , 4485–4491 (2003).
  • Rivoltini L , CarrabbaM, HuberV et al.: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.Immunol. Rev.188 , 97–113 (2002).
  • Belli F , TestoriA, RivoltiniL et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.J. Clin. Oncol.20 , 4169–4180 (2002).
  • Zeng Y , GranerMW, ThompsonS, MarronM, KatsanisE: Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.Blood105 , 2016–2022 (2005).
  • Li G , ZengY, ChenX et al.: Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.Clin. Exp. Immunol.148 , 136–145 (2007).
  • Cantrell J , LarmonierC, JanikashviliN et al.: Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.Immunobiology DOI: 10.1016/j.imbio.2009.09.006 (Epub ahead of print) (2009).
  • Larmonier N , CantrellJ, LacasseC et al.: Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression.J. Leukoc. Biol.83 , 1049–1059 (2008).
  • Li G , AndreanskyS, HelgueraG et al.: A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.Mol. Cancer Ther.7 , 721–729 (2008).
  • Kislin KL , MarronMT, LiG, GranerMW, KatsanisE: Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.FASEB J.21 , 2173–2184 (2007).
  • De Vries IJ , KrooshoopDJ, ScharenborgNM et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.Cancer Res.63 , 12–17 (2003).
  • Cheng F , WangHW, CuencaA et al.: A critical role for Stat3 signaling in immune tolerance.Immunity19 , 425–436 (2003).
  • Ueno H , KlechevskyE, MoritaR et al.: Dendritic cell subsets in health and disease.Immunol. Rev.219 , 118–142 (2007).
  • Bromberg JF , WrzeszczynskaMH, DevganG et al.: Stat3 as an oncogene.Cell98 , 295–303 (1999).
  • Wang T , NiuG, KortylewskiM et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.Nat. Med.10 , 48–54 (2004).
  • Kortylewski M , KujawskiM, WangT et al.: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent anti-tumor immunity.Nat. Med.11 , 1314–1321 (2005).
  • Burdelya L , KujawskiM, NiuG et al.: Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated anti-tumor effects.J. Immunol.174 , 3925–3931 (2005).
  • Evel-Kabler K , SongXT, AldrichM, HuangXF, ChenSY: SOCS1 restricts dendritic cells‘ ability to break self tolerance and induce anti-tumor immunity by regulating IL-12 production and signaling.J. Clin. Invest.116 , 90–100 (2006).
  • Melief CJ : Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?Eur. J. Immunol.33 , 2645–2654 (2003).
  • Vermi W , BonecchiR, FacchettiF et al.: Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas.J. Pathol.200 , 255–268 (2003).
  • Salio M , CellaM, VermiW et al.: Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions.Eur. J. Immunol.33 , 1052–1062 (2003).
  • Munn DH , SharmaMD, HouD et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.J. Clin. Invest.114 , 280–290 (2004).
  • Zhang M , TangH, GuoZ et al.: Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells.Nat. Immunol.5 , 1124–1133 (2004).
  • Gabrilovich DI , VeldersMP, SotomayorEM, KastWM: Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.J. Immunol.166 , 5398–5406 (2001).
  • Li Q , PanPY, GuP, XuD, ChenSH: Role of immature myeloid Gr-1+ cells in the development of anti-tumor immunity.Cancer Res.64 , 1130–1139 (2004).
  • Huang B , PanPY, LiQ et al.: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.Cancer Res.66 , 1123–1131 (2006).
  • Curiel TJ , CoukosG, ZouL et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.Nat. Med.10 , 942–949 (2004).
  • Larmonier N , MarronM, ZengY et al.: Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10.Cancer Immunol. Immunother.56 , 48–59 (2007).
  • Larmonier N , JanikashviliN, LaCasseCJ et al.: Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.J. Immunol.181 , 6955–6963 (2008).
  • Yang YA , DukhaninaO, TangB et al.: Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects.J. Clin. Invest.109 , 1607–1615 (2002).
  • Muraoka RS , DumontN, RitterCA et al.: Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases.J. Clin. Invest.109 , 1551–1559 (2002).
  • Uhl M , AulwurmS, WischhusenJ et al.: SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.Cancer Res.64 , 7954–7961 (2004).
  • Dannull J , SuZ, RizzieriD et al.: Enhancement of vaccine-mediated anti-tumor immunity in cancer patients after depletion of regulatory T cells.J. Clin. Invest.115 , 3623–3633 (2005).
  • Attia P , PowellDJ Jr, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA: Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J. Immunother.29 , 208–214 (2006).
  • North RJ : Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.J. Exp. Med.155 , 1063–1074 (1982).
  • Ghiringhelli F , LarmonierN, SchmittE et al.: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.Eur. J. Immunol.34 , 336–344 (2004).
  • Zeng Y , GranerMW, FengH, LiG, KatsanisE: Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat BCR-ABL+ murine leukemia.Int. J. Cancer110 , 251–259 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.